Once Weekly Carfilzomib Effective in Treatment-Naïve Multiple Myeloma
Multiple myeloma patients who received once-weekly carfilzomib with cyclophosphamide, dexamethasone had improved responses.
ASH 2014
Early Thymic Precursor Found to Lack Significance in Children with T-Lymphoblastic Leukemia (T-ALL)
The largest study of T-lymphoblastic leukemia (T-ALL) ever conducted demonstrated “an excellent outcome” with standard four-drug induction.
Minimal Residual Disease Negativity Predicts Prognosis in Mantle Cell Lymphoma
Minimal residual disease (MRD) negativity is the greatest independent predictor of prognosis in mantle cell lymphoma.
Rituximab Improves Outcomes for Treatment-Naïve Young Patients with Mantle Cell Lymphoma
Rituximab should be used as maintenance therapy for the treatment of young previously untreated patients with mantle cell lymphoma.
Prolonged Survival with Sorafenib Plus Standard Chemo in Younger Patients with Leukemia
Addition of sorafenib to standard chemotherapy for the treatment of younger patients with acute myeloid leukemia (AML) is effective.
Lenalidomide Induces Ubiquitination, Degradation of CSNK1A1 in Myelodysplastic Syndrome
Lenalidomide induces the ubiquitination and degredation of casein kinase 1A1 (CSNK1A1) by the CRBN-CRL4 E3 ubquitin ligase.
SAR650984 with Lenalidomide, Dexamethasone Induces Responses in Multiple Myeloma
Multiple myeloma treated with SAR650984 in combination with lenalidomide/dexamethasone see clinical benefit rate (CBR) of 65%.
Bilateral Involvement Is Independent Risk Factor in Testicular Relapse for Childhood Leukemia
Isolated testicular relapse in children with acute lymphoblastic leukemia (ALL) is associated with improved outcomes.
Drug Resistance in Primary Leukemia Due to Nanotube Signaling with Mesenchymal Stromal Cells
Disruption of tunneling nanotubules reduces the survival benefit that mesenchymal cells provide to primary acute lymphoblastic leukemia (ALL).
Adding Carfilzomib to Lenalidomide Improves Survival in Relapsed Multiple Myeloma
Adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma is clinically meaningful for progression-free survival.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2014
